Summary: In a within-trial economic evaluation of a completed cluster-randomised trial in 630 adults with type 2 diabetes and depressive symptoms across eight community health centres in China, the community-based integrated care model (CIC-PDD) yielded a cost per quality-adjusted life year (QALY) gained of $7,409 to $7,923 across health-system, multipayer and societal perspectives, with cost-effectiveness probabilities of 66 to 94 percent. The model was judged cost-effective within primary care, although this is an economic analysis rather than a fresh test of clinical efficacy.
PICO Summary
| Element | Detail |
|---|---|
| Population | 630 adults (≥18 years) with type 2 diabetes and depressive symptoms; within-trial economic evaluation nested in a completed cluster-randomised controlled trial across eight community health centres in China. |
| Intervention | Community-based Integrated Care Model for Patients with Diabetes and Depression (CIC-PDD), a comprehensive combined diabetes and mental-health care plan (n=275). |
| Comparison | Usual care: standard community diabetes management without integrated mental-health services (n=355). |
| Outcome | Cost per QALY gained: $7,922.82 (health system), $7,823.85 (multipayer), $7,409.46 (societal); cost-effectiveness probability 66.41% to 94.45%. Cost per depression-free day (DFD): $2.63 to $2.82, requiring a willingness-to-pay of $9.00 to $10.50 per DFD for >95% probability of cost-effectiveness. One-year time horizon; no incremental-effect 95% CI or p value reported for the primary cost-effectiveness ratios. |
Expert Commentary
This is a within-trial cost-effectiveness analysis, and on its own terms the verdict is favourable: the incremental cost per QALY gained, around $7,400 to $7,900, sits well below conventional willingness-to-pay thresholds, and the probability of cost-effectiveness reached as high as 94 percent under the societal perspective. The result is best read as an economic case for integrating depression care into community diabetes services, not as new proof of clinical efficacy, since the underlying effectiveness was established in the parent trial and is assumed here. The principal limitation is the one-year time horizon: durability of both the health gains and the cost offsets is unknown, and the authors themselves call for work on long-term sustainability and scalability. Generalisability is also constrained, as the costs, care structures and willingness-to-pay anchors are specific to Chinese primary care. No commercial sponsorship or implausibly large effect is evident, and the cluster-randomised design was, by nature, unblinded. Can I use this with my patients? Not directly as a clinical intervention from this paper, but it strengthens the policy and commissioning argument for co-locating depression screening and treatment within diabetes clinics where resources allow. Health systems weighing integrated multimorbidity care should treat these figures as a promising signal and press for longer-horizon, multi-setting confirmation before scaling.
References
Wang Y, Guo D, Xia Y, Hu M, Wang M, Shi Z, et al. Cost-effectiveness of community-based integrated care model for patients with diabetes and depressive symptoms. Nat Commun. 2025;16(1):2986. doi:10.1038/s41467-025-58120-x
